{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:15:20Z","timestamp":1782782120921,"version":"3.54.5"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma (MM) is a genetically complex disease. The key myeloma-initiating genetic events are hyperdiploidy and translocations involving the immunoglobulin heavy chain (IgH) enhancer on chromosome 14, which leads to the activation of oncogenes (e.g., CCND1, CCND3, MAF, and MMSET). The t(11;14) translocation is the most common in MM (15%\u201320%) and results in cyclin D1 (CCND1) upregulation, which leads to kinase activation and tumor cell proliferation. Notably, t(11;14) occurs at a higher rate in patients with plasma cell leukemia (40%) and light chain amyloidosis (50%). Patients with myeloma who harbor the t(11;14) translocation have high levels of the anti-apoptotic protein B-cell lymphoma 2 (BCL2). Multiple studies demonstrated that the presence of t(11;14) was predictive of BCL2 dependency, suggesting that BCL2 could be a target in this subtype of myeloma. Venetoclax, an oral BCL2 inhibitor, has shown remarkable activity in treating relapsed\/refractory MM patients with t(11;14) and BCL2 overexpression, either as monotherapy or in combination with other anti-myeloma agents. In this review, we describe the molecular defects associated with the t(11;14), bring into question the standard cytogenetic risk of myeloma patients harboring t(11;14), summarize current efficacy and safety data of targeted venetoclax-based therapies, and discuss the future of individualized or precision medicine for this unique myeloma subgroup, which will guide optimal treatment.<\/jats:p>","DOI":"10.3389\/fonc.2022.934008","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T06:17:23Z","timestamp":1659421043000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation"],"prefix":"10.3389","volume":"12","author":[{"given":"Michael D.","family":"Diamantidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Papadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdoxia","family":"Hatjiharissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-319-40320-5_3","article-title":"Genomic aberrations in multiple myeloma","volume":"169","author":"Manier","year":"2016","journal-title":"Cancer Treat Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.174","article-title":"International myeloma working group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197908)44:2<630::aid-cncr2820440233>3.0.co;2-g","article-title":"Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders","volume":"44","author":"Liang","year":"1979","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101153","article-title":"Genomic profiling of multiple myeloma: New insights and modern technologies","volume":"33","author":"Hultcrantz","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2017.05.001","article-title":"Multiple myeloma genomics: A systematic review","volume":"33","author":"Weaver","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic abnormalities in multiple myeloma: Prognostic and therapeutic implications","volume":"10","author":"Cardona-Benavides","year":"2021","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.6705","article-title":"Genomics of multiple myeloma","volume":"35","author":"Robiou du Pont","year":"2017","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_200879","article-title":"Risk stratification and targets in multiple myeloma: From genomics to the bedside","volume":"38","author":"Perrot","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.819127","article-title":"Where we stand with precision therapeutics in myeloma: Prosperity, promises, and pipedreams","volume":"11","author":"Pan","year":"2021","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100643","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.204","article-title":"Natural history of t(11;14) multiple myeloma","volume":"32","author":"Lakshman","year":"2018","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674","article-title":"Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines","volume":"88","author":"Chesi","year":"1996","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.2.380.380","article-title":"The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis","volume":"66","author":"Dewald","year":"1985","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francophone du my\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1981","article-title":"Relationship of patient survival and chromosome anomalies detected in metaphase and\/or interphase cells at diagnosis of myeloma","volume":"106","author":"Dewald","year":"2005","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22372","article-title":"Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable","volume":"55","author":"Leiba","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13325","article-title":"Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration","volume":"103","author":"Gran","year":"2019","journal-title":"Eur J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.538126","article-title":"What multiple myeloma with t(11;14) should be classified into in novel agent era: Standard or intermediate risk","volume":"10","author":"Gao","year":"2020","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41408-022-00638-0","article-title":"Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis","volume":"12","author":"Atrash","year":"2022","journal-title":"Blood Cancer J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1182\/blood-2021-150569","article-title":"Characterization of atypical t(11;14) CCND1\/IGH translocations in multiple myeloma","volume":"138","author":"Smadbeck","year":"2021","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000508234","article-title":"Ageism in the t(11;14) subtype of multiple myeloma","volume":"144","author":"Gonsalves","year":"2021","journal-title":"Acta Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.6.2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Avet-Loiseau","year":"2002","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-10-1066","article-title":"The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells","volume":"17","author":"L\u00f3pez-Corral","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16858","article-title":"Secondary plasma cell leukaemia treated with single agent venetoclax","volume":"190","author":"Glavey","year":"2020","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25331","article-title":"Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)","volume":"94","author":"Jelinek","year":"2019","journal-title":"Am J Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12986","article-title":"Combination therapy incorporating bcl-2 inhibition with venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)","volume":"100","author":"Gonsalves","year":"2018","journal-title":"Eur J Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.7.2266","article-title":"Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis","volume":"98","author":"Hayman","year":"2001","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-019-0177-9","article-title":"Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients","volume":"9","author":"Kazandjian","year":"2019","journal-title":"Blood Cancer J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41408-018-0132-1","article-title":"Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry","volume":"8","author":"Baughn","year":"2018","journal-title":"Blood Cancer J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33206","article-title":"Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray","volume":"127","author":"Chakraborty","year":"2020","journal-title":"Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403091","article-title":"t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma","volume":"17","author":"Garand","year":"2003","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2436","article-title":"Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants","volume":"101","author":"Avet-Loiseau","year":"2003","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/leu.2013.258","article-title":"Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma","volume":"28","author":"Greenberg","year":"2014","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1309\/4w8e-8f4k-bhup-ube7","article-title":"The (11;14)(q13;q32) translocation in multiple myeloma. a morphologic and immunohistochemical study","volume":"113","author":"Hoyer","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0223-9","article-title":"Targeting bcl-2 for the treatment of multiple myeloma","volume":"32","author":"Touzeau","year":"2018","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am J Hematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/blctt.s245191","article-title":"BCL2 family inhibitors in the biology and treatment of multiple myeloma","volume":"11","author":"Gupta","year":"2021","journal-title":"Blood Lymphat Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_159516","article-title":"New targets and new agents in high-risk multiple myeloma","volume":"35","author":"Nooka","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.287","article-title":"Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma","volume":"30","author":"Kaufman","year":"2016","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1182\/blood-2018-99-119051","article-title":"Outcomes of myeloma patients with t(11;14) receiving lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy","volume":"132","author":"Kaufman","year":"2018","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cncr.33208","article-title":"African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with whites in the united states","volume":"127","author":"Badar","year":"2020","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.11.003","article-title":"Clinical implications of t(11;14) in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"25","author":"Takamatsu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-0706","article-title":"Impact of autologous transplantation in patients with multiple myeloma with t(11;14): A propensity-score matched analysis","volume":"25","author":"Saini","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000003521","article-title":"Prognostic impact of cytogenetic abnormalities in multiple myeloma: A retrospective analysis of 229 patients","volume":"95","author":"Jian","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.216","article-title":"The bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","author":"Touzeau","year":"2016","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41408-020-0320-7","article-title":"\"Direct to drug\" screening as a precision medicine tool in multiple myeloma","volume":"10","author":"Bonolo de Campos","year":"2020","journal-title":"Blood Cancer J"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1548931","article-title":"Venetoclax for the treatment of multiple myeloma","volume":"11","author":"Vaxman","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-015-1344-5","article-title":"Interrelationship between angiogenesis, inflammation and oxidative stress in Indian patients with multiple myeloma","volume":"18","author":"Joshi","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.625199","article-title":"Game of bones: How myeloma manipulates its microenvironment","volume":"10","author":"Moser-Katz","year":"2020","journal-title":"Front Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01705.x","article-title":"Mcl-1 and bcl-xL are co-regulated by IL-6 in human myeloma cells","volume":"107","author":"Puthier","year":"1999","journal-title":"Br J Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: The role of cytokines in multiple myeloma","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediators Inflamm"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.006","article-title":"Revisiting IL-6 antagonism in multiple myeloma","volume":"105","author":"Matthes","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with b-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8511","article-title":"Updated analysis of a phase I\/II study of venetoclax in combination with daratumumab and dexamethasone, \u00b1 bortezomib, in patients with relapsed\/refractory multiple myeloma","volume":"38","author":"Kaufman","year":"2020","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00443","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.07.029","article-title":"A phase II study of venetoclax in combination with pomalidomide and dexamethasone in Relapsed\/Refractory multiple myeloma","volume":"21","author":"Gasparetto","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8554","article-title":"A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in ptients with t(11;14)-positive Relapsed\/Refractory multiple myeloma","volume":"38","author":"Mateos","year":"2020","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood-2021-145757","article-title":"Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in Relapsed\/Refractory multiple myeloma","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16454","article-title":"Real-world data on safety and efficacy of venetoclax-based regimens in relapsed\/refractory t(11;14) multiple myeloma","volume":"189","author":"Basali","year":"2020","journal-title":"Br J Haematol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26269","article-title":"Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials","volume":"96","author":"Sidiqi","year":"2021","journal-title":"Am J Hematol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13256-020-02376-y","article-title":"Venetoclax in combination with carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature","volume":"14","author":"Abuelgasim","year":"2020","journal-title":"J Med Case Rep"},{"key":"B81","doi-asserted-by":"publisher","first-page":"E68","DOI":"10.1002\/ajh.26064","article-title":"Natural history of multiple myeloma patients refractory to venetoclax: A single center experience","volume":"96","author":"Maples","year":"2021","journal-title":"Am J Hematol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-317438","article-title":"ABT-737 is highly effective against molecular subgroups of multiple myeloma","volume":"118","author":"Bodet","year":"2011","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Gomez-Bougie","year":"2018","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15073","article-title":"Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence","volume":"112","author":"Kitadate","year":"2021","journal-title":"Cancer Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4366","article-title":"Functional impact of genomic complexity on the transcriptome of multiple myeloma","volume":"27","author":"Ziccheddu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150370","article-title":"Identification of a novel drug sensitivity biomarker neuregulin-2 for venetoclax in non-t(11;14) multiple myeloma","volume":"138","author":"Dai","year":"2021","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0374-8","article-title":"Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma","volume":"33","author":"Matulis","year":"2019","journal-title":"Leukemia"},{"key":"B88","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood-2019-127593","article-title":"Mutations and copy number gains of the BCL2 family members mediate resistance to venetoclax in multiple myeloma (MM) patients","volume":"134","author":"Neri","year":"2019","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30587-8","article-title":"BELLINI: a renaissance for an era of precision therapy in multiple myeloma","volume":"21","author":"Ghobrial","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.934008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T06:17:26Z","timestamp":1659421046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.934008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":89,"alternative-id":["10.3389\/fonc.2022.934008"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.934008","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"article-number":"934008"}}